APOB and chronic kidney disease: Another possible mechanism to account for the results of our study is the impact on the catabolic rate of apolipoprotein B. Apolipoprotein B plays a fundamental role in the atherosclerotic process (31, 32), and in CKD patients, the catabolic rates of VLDL-apolipoprotein B are known to decrease (32).